ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib, a small rationally designed TKI by Tasigna; Novartis Pharmaceuticals Corporation, is good inhibitor of BCR-ABL and is approved for imatinib-resistant CML.